Excellent
Patient Risk:
Low
Summary
The provided claims about abiraterone acetate dosing frequency and administration (empty stomach timing, prednisone schedule by indication, and CYP3A4 inducer-related dose-frequency adjustment) are directly supported by the cited FDA label sections. No dosing contradictions or unsafe off-label promotion are evident within the evaluated scope.
Category Scores
Accurate Statements
Abiraterone acetate tablets must be taken as a single dose once daily on an empty stomach, with no food 2 hours before and 1 hour after dosing, and swallowed whole with water (do not crush or chew).
Label 2.3 Important Administration Instructions: “must be taken as a single dose once daily on an empty stomach. Do not eat food 2 hours before and 1 hour after…” and “swallowed whole with water. Do not crush or chew tablets.”
For metastatic CRPC: abiraterone acetate 1,000 mg (four 250 mg tablets) orally once daily with prednisone 5 mg orally twice daily.
Label 2.1 Recommended Dose for Metastatic CRPC and Label 1 INDICATIONS AND USAGE (combination with prednisone).
For metastatic high-risk CSPC: abiraterone acetate 1,000 mg (four 250 mg tablets) orally once daily with prednisone 5 mg orally once daily.
Label 2.2 Recommended Dose for Metastatic High-risk CSPC and Label 1 INDICATIONS AND USAGE (combination with prednisone).
Abiraterone acetate dosing frequency should be increased to twice daily only during co-administration of a strong CYP3A4 inducer (during the co-administration period).
Label 7.1 Drugs that Inhibit or Induce CYP3A4 Enzymes: “increase… to twice a day only during the co-administration period.”
Unsupported Statements
Contradictions
Important Omissions
Monitoring for hypertension, hypokalemia, and fluid retention at least once a month and correcting hypertension/hypokalemia before and during treatment.
Importance:
Moderate
Requirement to receive a GnRH analog concurrently or to have had bilateral orchiectomy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Within the evaluated scope (dosing/administration and drug-interaction-based dosing frequency), the claims match label directions. However, important label elements related to concurrent GnRH therapy and safety monitoring were not included in the presented response scope, which could matter for safe use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Primary Issue
Omission of key label safety/adjunct requirements (GnRH analog/orchiectomy concurrent requirement and monthly monitoring for hypertension/hypokalemia/fluid retention).
Suggested Improvement
Add the label’s concurrent GnRH analog/bilateral orchiectomy requirement and the minimum monthly monitoring and correction guidance for hypertension/hypokalemia/fluid retention to better reflect the full label safety instructions.